Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario

Xlife Sciences AG / Key word(s): Miscellaneous

09-May-2022 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

Xlife Sciences AG (SIX: XLS) today for the first time published an independent assessment of its project portfolio and intends to issue this report annually from now on.

The extensive Valuation Report as of December 31, 2021 identified a valuation range of CHF 574 million up to CHF 701 million. The average value of this range corresponds to more than a factor of 2.5 compared to the current market capitalization of Xlife Sciences and thus underlines the attractive price-earnings ratio of approx. 4. Approximately 90 percent of the determined value is attributable to the “top 10” projects, which include, among others, the project companies Veraxa Biotech, alytas therapeutics, inflamed pharma, Quadira Biosciences, and Inventum Genetics. The report also highlights the broad risk diversification of the portfolio and shows the extensive access to the life sciences sector for investors.

The valuation was performed by the independent consulting firm Cylad Experts and is primarily based on the risk- adjusted present value method typically used in the life sciences industry. The central parameters used for the valuation process are thus the cost of capital and the development risks of the project companies. Three of the 23 project companies will be included in the next evaluation in 2022.

Oliver R. Baumann, CEO of Xlife Sciences, comments: “With the Valuation Report, we are pleased to present investors for the first time with a complete and independent valuation of our project companies. We are convinced that this report soundly demonstrates and explains the future, long-term potential of our project portfolio. In 2022, further projects have already reached important milestones, underlining the sustainability of the Valuation Report’s assessment.”

The complete Valuation Report is available for download in German at www.xlifesciences.ch/news-kennzahlen and in English at www.xlifesciences.ch/en/news-and-key-figures.

Financial calendar

Ordinary General Assembly 2022 June 20, 2022

2022 Half-Year Results September 28, 2022

Information for journalists:

IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors:

Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
ISIN: CH0461929603
Börsen: SIX Swiss Exchange  

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch


Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

End of ad hoc announcement

show this